Adagio Therapeutics, Inc. ADGI
Set alert
At close
52-week range unavailable
- Open
- 4.62
- Prev close
- 4.64
- Mkt cap
- 504.98M
- Vol
- 535.00K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.40
- High
- 4.74
- Forward P/E
- -2.34
- Beta
- 0.00
- Short ratio
- 8.85
- Inst. own
- 71.59%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 15, 2022
- 50-d avg
- 4.18
- 200-d avg
- 4.78
- 1y target
- 3.83
Key statistics
- Market cap
- 504.98M
- Enterprise value
- 31.86M
- Trailing P/E
- 0.00
- Forward P/E
- -2.34
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.22
- EPS (TTM)
- -2.63
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 474.88M
- Total debt
- 2.86M
- Return on equity
- 0.00%
- Shares outstanding
- 108.83M
- Short % of float
- 21.14%
- 50-day average
- 4.18
- 200-day average
- 4.78
Analyst view
Consensus: hold
- Target (low)
- 3.00
- Target (mean)
- 3.83
- Target (high)
- 5.00
Next earnings
Aug 15, 2022
Expected Aug 15, 2022. Consensus EPS estimate -0.49.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 15, 2022 | Jun 1, 2022 | -0.55 | — | — | — |
| May 13, 2022 | Mar 1, 2022 | -0.63 | — | — | — |
| Mar 31, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 15, 2021 | Sep 1, 2021 | -0.68 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 16, 2022 | Morgan Stanley | main | — | Underweight |
| May 17, 2022 | Morgan Stanley | main | — | Underweight |
| Jan 6, 2022 | Morgan Stanley | down | Equal-Weight | Underweight |
| Dec 22, 2021 | Jefferies | down | Buy | Hold |
| Dec 15, 2021 | Morgan Stanley | down | Overweight | Equal-Weight |
| Dec 15, 2021 | Guggenheim | down | Buy | Neutral |
About Adagio Therapeutics, Inc.
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- adagiotx.com
News
- Adagio Therapeutics to Participate in Upcoming Investor Conferences
- Hedge Fund M28 Capital Increases Adagio Therapeutics (ADGI) Stake to 8.5%
- Why MSP Recovery Is Trading Higher By Over 21%, Here Are 61 Stocks Moving In Monday's Mid-Day Session
- Stocks That Hit 52-Week Lows On Wednesday
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Monday
- Stocks That Hit 52-Week Lows On Friday
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Monday
- Adagio's (ADGI) COVID-19 Antibody Meets Goals in Studies
Your note
Sign in to keep a note on ADGI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADIMAB, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 9, 2021 | 27,846,000 |
| ELIA MARC | Director | Purchase | Aug 18, 2022 | 0 |
| GERNGROSS TILLMAN U. | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 9, 2021 | 0 |
| HERING DAVID | Chief Executive Officer | Purchase | Aug 31, 2022 | 8,000 |
| MCGUIRE TERRANCE G | Director | Purchase | Aug 9, 2021 | 0 |
| MITHRIL II, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 9, 2021 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.00% | 15,233,411 | 70.68M | Jun 29, 2022 |
| M28 Capital Management LP | 5.88% | 6,398,250 | 29.69M | Jun 29, 2022 |
| Orbimed Advisors LLC. | 4.65% | 5,056,000 | 23.46M | Jun 29, 2022 |
| Slate Path Capital, LP | 3.43% | 3,735,000 | 17.33M | Jun 29, 2022 |
| 683 Capital Management LLC | 3.31% | 3,603,637 | 16.72M | Jun 29, 2022 |
| Vanguard Group, Inc. (The) | 3.03% | 3,302,268 | 15.32M | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 4.65% | 5,063,830 | 23.50M | Jul 30, 2022 |
| Vanguard Total Stock Market Index Fund | 1.49% | 1,620,200 | 7.52M | Jun 29, 2022 |
| Fidelity Growth Company K6 Fund | 1.22% | 1,332,104 | 6.18M | Jun 29, 2022 |
| iShares Russell 2000 ETF | 1.14% | 1,237,908 | 5.74M | Jul 30, 2022 |
| Fidelity Series Growth Company Fund | 1.13% | 1,230,517 | 5.71M | Jun 29, 2022 |
| Vanguard Small-Cap Index Fund | 0.64% | 691,956 | 3.21M | Jun 29, 2022 |